GCP指南中英文对照.docx
![资源得分’ title=](/images/score_1.gif)
![资源得分’ title=](/images/score_1.gif)
![资源得分’ title=](/images/score_1.gif)
![资源得分’ title=](/images/score_1.gif)
![资源得分’ title=](/images/score_05.gif)
《GCP指南中英文对照.docx》由会员分享,可在线阅读,更多相关《GCP指南中英文对照.docx(5页珍藏版)》请在淘文阁 - 分享文档赚钱的网站上搜索。
1、GCP基础指南中英文双语对照来源:发布时间:2010-7-14我要评论(3)分享到:0Tags: GCPIntroduction前言(赵宁翻译 meking第一次校对cassals第2次校对)The overall aim of this work is to provide a reference book which describes the general framework for conducting GCP-compliant clinical research, particularly pharmaceutical industry clinical research. Ho
2、pefully, it is written in simple enough language so that it is readable to those who are new to the business: however, we have also included many examples from our years of practice to sustain the interest of a more experienced group. Pharmaceutical industry personnel (e.g. monitors, data management
3、 personnel, statisticians, medical advisers, and study medication or device suppliers from both sponsors and CROs) will find many helpful hints and examples of how the situation can go awry. We also hope the book will be of value to new and experienced personnel at clinical study sites including inv
4、estigators, research nurses, study site coordinators, clinical laboratory staff and pharmacists. Members of ethics committees and IRBs should find this reference book useful to increase their understanding of how clinical research operates from the perspective of the pharmaceutical industry, and aud
5、itors and inspectors will especially find the book helpful because of the numerous references to audit findings. There might be interest from an academic perspective as well.编写这本书的目的是为执行依从GCP的临床试验提供一本描述总体框架的参考书,特别是针对制药企业的临床试验。本书尽量以通俗的语言编写,以期那些刚刚进入临床研究领域的新手们也能读懂。然而,我们在这本书中也引用了许多实例都是我们多年来有经验的组织在执行上所关注
6、的议题。制药企业的工作人员(如监查员、数据管理人员、统计学家、医学顾问以及给申办者和CRO公司供应药物或设备的供应商等)会发现许多关于如何歪曲临床研究结果的有益提示和实例。我们也希望这本书对新的和经验丰富的临床基地的工作人员(包括研究者、研究护士、基地协调员、临床实验室人员和药剂师)来说也很有参考价值。伦理委员会/机构审查委员会的成员会发现,这也是一本有用的参考书籍,可以加强他们了解制药企业是如何操作临床试验的。尤其是稽查者和视察者会发现这本书很有帮助,因为本书引用的大量资料皆是来自于稽查者在执行稽查时的发现。从学术角度来看,本书也是很有意义的。First of all, we should
7、make it clear that in our opinion there is no such thing as a fully GCP-compliant clinical study. It is almost impossible to achieve the ideal proclaimed in the existing guidelines and regulations. However, this does not mean we should not strive for the best standard possible. You must think beyond
8、 the minimum standard if you really want to do a good job and ensure the best quality possible. Slavish adherence to guidelines and regulations will not work: you must be convinced of the basic logic, ethics and science behind GCP requirements. Going for the most expedient and cheapest route will no
9、t only result in a poorer standard but it may also cost lives.首先,我们应该清楚,在我们看来,没有完全依从GCP的临床研究,完美遵从目前指导原则和法规几乎是不可能的。但是,这并不意味着我们就不应该尽可能达到最好的标准。如果你确实想要做好工作并尽可能确保高质量,就必须考虑超过最低标准。机械的遵从指导原则和法规是没有用的,但必须遵循GCP要求的基本的逻辑、伦理和科学原则。一味的寻求最方便、最便宜的途径将不仅仅导致一个更低的标准,也可能增加成本。 How much non-compliance should we tolerate? In
10、 1996, we published a book on GCP compliance based on the findings of our audit experience at 226 investigator study sites, involving studies conducted in 20 different countries, and audited by an independent external audit team between 1991 and 1995. GCP compliance was compared for various factors
11、and the data patterns suggested some interesting trends. First, the overall level of GCP compliance was generally poor across all investigator study sites and far below the expectations of guidelines and regulations. (In many areas, the studies were possibly dangerous for study subjects, in our opin
12、ion.) Second, there were no important differences in studies with regard to the year in which the study was conducted. Basically, all the new regulatory efforts, particularly in Europe, did not show a positive effect on standards.(However, a survey over a five- to six-year time period is possibly to
13、o limited to draw conclusions on this point.) Third, there were no important differences in studies which used a CRO (contract research organization) compared to those which did not. This appears to be because CROs simply follow the standards of the sponsor responsible for the conduct of the study r
14、ather than setting consistent and better standards themselves. Fourth, some slight differences between phases of studies were observed, with better compliance in early phase studies. However, this should not be surprising since a Phase I single-centre study with 20 subjects is much easier to control
15、 than a Phase III multicentre multinational study involving several hundred study subjects. Fifth, there were some slight differences between therapeutic areas, but this was probably linked to the standards of the sponsor or CRO managing the studies. Sixth, overall, there were no basic overall diffe
16、rences between levels of GCP compliance in different countries. (However, a later analysis of selected items showed some individual differences between countries: for example, direct access to source documents was achieved 100% of the time at US sites, but not as frequently in other countries.)The o
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- GCP 指南 中英文 对照
![提示](https://www.taowenge.com/images/bang_tan.gif)
限制150内